Jump to:

Domperidone cardiac warning

01 February 2012, 9:12am

The MHRA has issued guidance regarding the risk of QT prolongation in patients treated with domperidone.

Patients should seek prompt medical attention if symptoms such as syncope or tachyarrhythmia appear during treatment | SCIENCE PHOTO LIBRARY

Patients should seek prompt medical attention if symptoms such as syncope or tachyarrhythmia appear during treatment | SCIENCE PHOTO LIBRARY

Two studies have shown that domperidone may increase the risk of serious ventricular arrhythmias or sudden cardiac death, particularly in patients older than 60 years or taking doses greater than 30mg daily.

Domperidone should be avoided in patients taking medication that causes QT prolongation. Caution is required when treating patients with prolonged cardiac conduction intervals, significant electrolyte disturbances or underlying cardiac disease.

The lowest effective dose should be used and patients should seek prompt medical attention if symptoms such as syncope or tachyarrhythmia appear during treatment.

You must log in to make full use of all the site content and features.

New users can register here free for full site access.

Related Drug Categories

 

MIMS Specialist Journals

Now available on www.mims.co.uk

Click here to view

MIMs Drug Search

Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.

Find drugs by:

NICE Guidance: IBS

NICE Guidance: IBS

MIMS Summary of
NICE guideline

NICE Guidance: Lipid Modification

NICE Guidance: Lipid Modification

MIMS Summary of
NICE guideline

Quick-reference table: antibiotics

Quick-reference table: antibiotics

Treatment regimens for common infections

Referral Guidelines for Breast Disorders

Referral Guidelines for Breast Disorders

MIMS Summary of NHS Cancer Screening Referral Guidelines

Back to top